Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Drug Discovery Centralization Brings R&D Relocations, Job Cuts

Executive Summary

Novartis' efforts to rationalize and centralize its drug discovery programs will see the Novartis Institute for Tropical Diseases moved from Singapore to California and the closure of biologics units in Shanghai and in the Swiss town of Schlieren.

You may also be interested in...



Nothing Is Undruggable: Novartis' Bradner On CAR-T, CRISPR & DNA Libraries

The head of Novartis' early drug discovery engine NIBR has a zealous sense of mission and says he is being given the resources and talent to accomplish it. "Nothing is undruggable," is his premise.

Asia Attracts Manufacturing Capital As Companies Eye Expanding Needs

Life science and pharma companies have been actively investing in Asia over the past month as they look to increase regional manufacturing capacities to tap into burgeoning markets and meet rising demand for new technologies, biologics and high-quality products, while Chinese firms have also been expanding their international presence.

Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big

Novartis is closing its high-profile cell and gene therapy unit – the one responsible for developing CAR-T therapies. The move suggests Novartis’s outlook for the CAR-T field may be changing, though it’s not clear why.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097432

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel